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Long-term ultraviolet light exposure of human skin
epidermis in Caucasians is associated with an
increased risk for the development of melanoma and
nonmelanoma skin cancers. Ultraviolet radiation not
only induces DNA damage in epidermal cells, it also
interferes with skin homeostasis, which is maintained
by a unique distribution pattern of apoptosis-induc-
ing and apoptosis-preventing molecules. We demon-
strate that, beside CD95 ligand, TRAIL and TRAIL
receptors also function as important sensors in the
human epidermis preserving skin integrity and pre-
venting cell transformation. Ultraviolet irradiation
extensively changes the expression pattern of some
of these molecules, diminishing their sensor function.
In particular, CD95 ligand and to a somewhat lesser
extent TRAIL receptors are downregulated upon
ultraviolet light exposure. CD95 ligand downregula-
tion is not due to protein degradation as in situ
hybridization experiments strongly support a tran-
scriptional regulation. The downregulation of these
molecules with sensor function increases the risk that
aberrant cells are less ef®ciently eliminated. This
concept is supported by the fact that the expression
of these molecules is also low or absent in actinic
keratosis, a precancerous state that has developed as
the consequence of long-term ultraviolet exposure.
Progression to invasive neoplasms is then accom-
panied by an upregulation of CD95 ligand and a
downregulation of CD95 and of the TRAIL recep-
tors. The high expression of CD95 ligand, TRAIL,
and FLIP in squamous cell carcinoma may then con-
tribute to the immune escape of the tumor, whereas
the lack of expression of CD95 and TRAIL receptors
prevents autolysis of the tumor. Key words: apoptosis/
death ligands/death receptors/immune escape/skin tumors.
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A
ccording to the World Health Organization
2,000,000 nonmelanoma skin cancers and 200,000
malignant melanomas occur globally each year and an
additional 300,000 skin cancers and 4500 melanomas
are expected worldwide due to decreasing ozone
levels and the corresponding increased ultraviolet (UV) light
intensity (WHO/EHG/95.16). The skin is the ®rst target of UV
exposure and its damaging effects. Nonmelanoma skin cancers
predominantly consist of basal cell carcinoma (BCC) and squamous
cell carcinoma (SCC). BCC is the most common malignant
neoplasm among white persons. The results of UV radiation
exposure seem to differ with respect to the development of
nonmelanoma skin cancers and melanomas, cumulative exposures
being more important in the development of nonmelanoma skin
cancers, particularly SCC (Marks, 1995). Actinic keratoses (AK) are
proliferations of transformed, neoplastic keratinocytes con®ned to
the epidermis that occur as a result of long-term overexposure of
the skin of fair-skinned Caucasians to the sun's UV light. It has
been reported that about 10% of AK progress to invasive SCC
(Glogau, 2000).
Apoptosis, or programmed cell death, is a major cellular
homeostatic mechanism in normal skin and plays an important
role in the defense against damaged or transformed cells. As a
response to UV-light-mediated DNA damage the tumor suppressor
protein p53 is upregulated and ``sunburn cells'' are removed by
apoptosis (Hall et al, 1993; Henseleit et al, 1997). The rate of
apoptosis induced by UV radiation is signi®cantly reduced in
keratinocytes of p53 knockout mice (Ziegler et al, 1994). The loss
of p53 function by mechanisms such as UV-induced mutations
reduces the capacity of p53 to trigger cell death, leading to
increased proliferation or tumorigenesis of the cells (Brash et al,
1996). UV irradiation causes unique mutations in the p53 gene,
which have been found in most human skin cancers such as SCC,
BCC, as well as in AK. Although there is evidence that p53 is a
major regulator of UV-induced apoptosis in keratinocytes, p53-
independent apoptotic pathways also exist (Gniadecki et al, 1997).
Recently, Hill et al (1999) showed using a mouse model that UV
light transiently upregulated CD95 and CD95 ligand (CD95L) in
keratinocytes, whose interaction eliminated ``sunburn cells'' by
apoptosis, thus preventing UV-induced p53 mutations. Their
results strongly indicate that CD95L-mediated apoptosis is import-
ant for homeostasis of the human epidermis and that a dysregulation
of CD95L±CD95 interaction may be crucial for the development
of skin cancer. CD95L and its receptor are important extrinsic
Manuscript received December 15, 2000; revised March 14, 2001;
accepted for publication March 15, 2001.
Reprint requests to: Dr. Peter Erb, Institute for Medical Microbiology,
University of Basel, Petersplatz 10, CH-4003 Basel, Switzerland. Email:
peter.erb@unibas.ch
Abbreviations: AK, actinic keratosis; BCC, basal cell carcinoma; FLIP,
¯ice inhibitory protein; GFP, green ¯uorescence protein; ISH, in situ
hybridization; TRAIL, tumor-necrosis-factor-related apoptosis-inducing
ligand.
1These authors contributed equally to this work.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
59
inducers of cell apoptosis belonging to the tumor necrosis factor
(TNF) superfamily. Another extrinsic inducer of cell death is TNF-
related apoptosis-inducing ligand (TRAIL) (Suda et al, 1993, 1995;
Nagata and Golstein, 1995), which interacts with four death
receptors TRAIL-R1 to TRAIL-R4, but two of them, TRAIL-
R3 and TRAIL-R4, do not induce the apoptotic pathway
(MacFarlane et al, 1997; Pan et al, 1997a, b; Schneider et al,
1997; Sheridan et al, 1997). The biologic function of these ``decoy''
receptors is not entirely clear. Upon CD95±CD95L or TRAIL±
TRAIL-R1/R2 interaction adaptor proteins, such as FADD or
TRADD, are recruited that facilitate the binding and activation of
caspase-8 to the receptor complex (reviewed by Walczak and
Krammer, 2000). Subsequently, activated caspase-8 cleaves other
caspases inducing the apoptotic pathway. An antiapoptotic mole-
cule is ¯ice inhibitory protein (FLIP), which can prevent CD95- or
TRAIL-R-mediated apoptosis by competing with the adaptor
molecules for caspase-8 binding (Irmler et al, 1997). Important
intrinsic antiapoptotic molecules are Bcl-2 and Bcl-xL (reviewed
by Adams and Cory, 1998).
In normal human skin, CD95 is variably expressed in the
epidermis, dermal adnexae, endothelial cells, ®broblasts, and some
melanocytes (LeithaÈuser et al, 1993; Oishi et al, 1994; Lee et al,
1998). CD95L is expressed in normal human skin, especially in the
epidermis, sebaceous and eccrine glands, and blood vessels (Lee et al,
1998). Moreover, constitutive expression of CD95L was found in
BCC and SCC (Strand et al, 1996; Buechner et al, 1997; Gutierrez-
Steil et al, 1998; Lee et al, 1998). The signi®cance of CD95 and
CD95L expression in the epidermis is also highlighted by the
development of skin diseases following a dysregulation of the death
ligand. For example, hyperplastic keratinocytes in untreated
psoriatic plaques do not express CD95L, presumably supporting
their unrestricted proliferation (Gutierrez-Steil et al, 1998). In
contrast, Viard et al found high expression of CD95L on
keratinocytes in Lyell's syndrome and demonstrated a direct
involvement of CD95±CD95L interactions in the epidermal
necrolysis (Viard et al, 1998).
The expression of TRAIL and its receptors in the epidermis is
not well documented. Both primary and transformed keratinocytes
express TRAIL-R (Leverkus et al, 2000) and TRAIL transcripts
and proteins were also found in keratinocytes and in the cell lines
HaCaT and KB, but only the cell lines and not the keratinocytes
were reported to be sensitive to TRAIL-mediated apoptosis
(Kothny Wilkes et al, 1998). The putative role of TRAIL and its
receptors in the epidermis is so far unknown, however. As TRAIL
induces apoptosis in a wide variety of transformed cell lines (Wiley
et al, 1995; Grif®th and Lynch, 1998; Walczak et al, 1999), it could
serve in the epidermis as an important additional guardian beside
CD95L against cell transformation.
Here, we report that various apoptosis-inducing and apoptosis-
preventing molecules are differently expressed in sunlight-exposed
and in sunlight-protected epidermis. Moreover, sunlight exposure
weakens the sensor function of certain death molecules through
UV irradiation, increasing the risk for development of cancers of
the skin.
MATERIALS AND METHODS
Skin specimens The normal human epidermis used was either split-
skin obtained from seven patients undergoing plastic surgery, foreskin
from ®ve children (age 1±8 y) undergoing circumcision, or biopsies from
three healthy volunteers and from two long-term sun-exposed
individuals (>6 mo). Informed consent was obtained from the
volunteers. Biopsy specimens from 12 AK and four SCC were
investigated. Parts of the biopsy specimens were ®xed in 4% buffered
formaldehyde and embedded in paraf®n and/or snap-frozen in liquid
nitrogen. Paraf®n sections (4 mm) or cryosections (6 mm) were made and
used for in situ hybridization (ISH), in situ apoptosis detection, and
immunohistochemistry.
UVB radiation An area of 3 3 3 cm of non-sun-exposed skin on the
buttock of a healthy volunteer was irradiated with 0.2 J per cm2 UVB
using a Waldmann UV3003K bank (Herbert Waldmann, Schwenningen,
Germany). Before and 14 h, 38 h, 72 h, and 132 h postradiation biopsies
were taken and snap-frozen in liquid nitrogen.
Antibodies Rabbit polyclonal antibodies were raised and immuno-
puri®ed according to standard procedures. Antibodies against human
FLIP and human TRAIL were raised by using GST fusion proteins,
whereas antibodies recognizing TRAIL-R (TRAIL-R1, TRAIL-R2,
and TRAIL-R3, also called DcR1) were raised against peptides (Anawa
Trading, Wangen, Switzerland) coupled to KLH (Sigma, Buchs,
Switzerland). The following speci®c peptides were used: TRAIL-R1
(SKVWGSSAGRIEPRGGGRGA), TRAIL-R2 (CKSLLWKKVLP-
YLKGIC), and TRAIL-R3 (AEETMTTSPGTPASSHYLSC). The
coupling of the peptides to KLH was done according to standard
procedures. All antibodies raised against GST fusion proteins and KLH-
coupled peptides, respectively, were additionally preabsorbed against
bacterial lysate from mock transformed Escherichia coli or against KLH
coupled to Sepharose 4B (Pharmacia Biotech Europe, DuÈbendorf,
Switzerland). As control, appropriate isotype control antibodies or
preimmune sera were used in comparable dilutions. The speci®city of
the antibodies was determined by Western blots (Fig 1b, c) and by
competition in immunostainings (Fig 1d). To test for speci®city for
immunostaining, the TRAIL, TRAIL-R, and FLIP antibodies were
preincubated with the corresponding or wrong peptides (TRAIL-R1/
R2) or recombinant proteins (TRAIL, FLIP) and tested in normal skin
sections. Preabsorbing with the corresponding but not with the wrong
peptides/proteins fully or partially abolished the staining property of the
antibodies, con®rming their high speci®city (Fig 1d). The other
antibodies used were a rabbit antihuman CD95L antibody that has been
described elsewhere (Buechner et al, 1997) and monoclonal antibodies
directed against Bcl-2 (clone 100, Ancell Corporation, Bayport, MN),
p53 (clone DO-1, Oncogene Research, Cambridge, MA), and CD95
(clone B-G27, Diaclone, Besancon, France).
Production of GST fusion proteins Parts of hFLIP and hTRAIL
were polymerase chain reaction (PCR) cloned using the pGEM-T-easy
vector system (Promega Corporation, Madison, WI). The following
primers were used: FLIP, 5¢-position 383±404, 3¢-position 962±985 in
the published cDNA (AC U97074); TRAIL, 5¢-position 169±194, 3¢-
position 825±846 in the published cDNA (AC U37518). Using
appropriate restriction sites introduced into the primers the subcloned
fragments were ligated into the pGEX5X-1 vector (Pharmacia Biotech
Europe) for expression purposes. Puri®cation of the resulting GST fusion
proteins was done according to the manufacturer's protocol.
Immunohistochemistry Immunohistochemistry on paraf®n sections
or cryosections was done as described earlier (Buechner et al, 1997). The
monoclonal antibody to p53 worked on paraf®n sections only whereas
the monoclonal antibody to CD95 only stained cryosections. All other
antibodies used worked better on cryosections than on paraf®n sections.
In situ hybridization A digoxigenin-labeled RNA hybridization probe
of 344 bp (Bennett et al, 1998) was generated corresponding to codons
96±210 of the human CD95L cDNA sequence. The riboprobe was
synthesized by in vitro transcription using digoxigenin-11-UTP and T7
RNA polymerase (Roche Molecular Biochemicals, Mannheim,
Germany) according to the manufacturer's protocol. The template for
the in vitro transcription reaction was generated by PCR ampli®cation of
a fragment corresponding to codons 96±210 of the human CD95L
cDNA using a Taq DNA Polymerase (Gibco BRL, Life Technologies,
Basel, Switzerland) and an antisense primer to which a T7 promoter was
added (Bennett et al, 1998). The following PCR cycling conditions (35
cycles) were used: denaturation at 95°C for 30 s, annealing at 60°C for
30 s, and extension at 72°C for 1 min and 30 s. An unlabeled riboprobe
was also generated for use in competitive control hybridizations.
The ISH were performed on 4 mm thick paraf®n sections of human
skin biopsies. Prehybridization and hybridization treatments were per-
formed according to the manufacturer's protocol for the BioGenex
``Super Sensitive'' ISH kit (Stehelin, Basel, Switzerland). Hybridized
probe was detected immunologically using alkaline phosphatase conjug-
ated sheep antidigoxigenin antibody (Roche Molecular Biochemicals)
and visualized with nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl
phosphates (NBT/BCIP). In the control hybridizations, a 10-fold excess
of unlabeled riboprobe to the digoxigenin-labeled riboprobe was used.
This resulted in a marked reduction of the signal, thus con®rming the
speci®city of the hybridizations.
Terminal deoxynucleotidyl-transferase-mediated dUTP nick end
labeling (TUNEL) Apoptosis in paraf®n sections or cryosections was
determined by the TUNEL technique according to the manufacturer's
protocol (Roche Molecular Biochemicals).
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Computer-assisted image analysis quanti®cation The immuno-
stainings were photographed using a digital CCD color camera (CF 20
DXC air, Kappa Messtechnik, Gleichen, Germany) on an inverted
microscope (Nikon, Diaphot 300, Tokyo, Japan) at an original magni®c-
ation of 2003. All pictures were taken under the same conditions. The
quantitative analysis was performed for the immunostainings of the
epidermis of the same individual before and after UV exposure using
skin sections that were immunostained under the same conditions at the
same time. The quanti®cations were performed on a Nikon Eclipse
TE200 inverted microscope using a Hamamatsu digital camera and
controller (Bucher, Basel, Switzerland). For scienti®c imaging the
Openlab program was used (Improvision, Coventry, U.K.). The region
of interest was arbitrarily de®ned choosing an epidermal area of 20,000±
40,000 pixels. The maximum, minimum, and mean, which record the
equivalent gray-level intensity within the region of interest, were
determined. Three persons independently determined regions of interest
in at least three different skin sections. The mean intensity values of the
isotype or preimmune controls were subtracted from the mean intensity
values of the corresponding antibodies. For calculation, the subtracted
mean values of the skin measurements obtained before UVB irradiation
were set to 1.0 (relative gray-scale index) with an exception for
CD95 for which the 132 h postirradiation mean value was set to 1.0.
All stainings were set in relation to the index of 1.0. The quanti®cations
calculated do not take into account that some markers are differently
expressed in the basal and upper layers. Statistical analysis was
performed using the unpaired Student's t test; p < 0.05 was considered
signi®cant.
Western blots Western blot analysis of tissue culture cells and human
skin specimens was done according to a protocol described elsewhere
(Bachmann et al, 1997). The following modi®cations were used. Frozen
split-skin specimens were mechanically minced into small pieces in liquid
nitrogen by using a mortar and then subsequently incubated in STE
buffer. Finally, 30 mg protein per lane originating either from tissue cell
extract or split-skin specimen were separated on a minigel and
subsequently blotted onto a nitrocellulose membrane (Schleicher-Schuell,
Dassel, Germany) at 1 mA per cm2 for 60 min. After overnight
incubation with the primary rabbit antibody at 4°C, a second swine
antirabbit peroxidase coupled antibody (1 h at room temperature)
(1:2000, Dako, Glostrup, Denmark) was used. The protein±antibody
complexes were then visualized by enhanced chemiluminescence
(Amersham International) according to the manufacturer's protocol.
Cells HaCaT and HL60 cell lines were cultured in RPMI 1640
medium (Gibco) containing 10% heat-inactivated fetal bovine serum
(FBS; Gibco) and 2 mM L-glutamine (Gibco) at 37°C and 7.5% CO2.
Green ¯uorescence protein (GFP)-Jurkat and GFP-A20 target cells were
kept in RPMI containing 5% FBS, 2 mM L-glutamine, and 0.05 mM
b-mercaptoethanol (Gibco).
Functional assay for CD95L and TRAIL After surgery, foreskin or
split-skin specimens were immediately submerged in serum-free
keratinocyte basal medium (Sigma) including gentamycin (100 mg per
ml; Gibco) at 4°C and were processed within 2 h. Connective tissue and
fat (foreskin) were removed and the specimens were cut into small pieces
(2±3 mm) with scissors, washed three times in Iscove's medium without
FBS (Gibco), and distributed into several ¯uorescence-activated cell
sorter tubes. Medium alone or containing CD95-Fc, TRAIL-R1-Fc
(each 2 mg per ml; Alexis, Sissach, Switzerland), CD40-Fc (1 mg per ml,
kindly provided by Dr. P. Lane, Basel Institute for Immunology), or
human IgG (2 mg per ml, Sigma) was added to the tubes and incubated
at 37°C and 7.5% CO2 for 30 min in a humi®ed incubator.
Subsequently, 2 3 105 GFP-Jurkat cells were added as targets, which
were either preincubated for 1 h at 37°C with caspase inhibitor zVAD,
control zFA (each at 20 mM, Enzyme Systems Products, Dublin, CA),
and dimethylsulfoxide 1:500 or kept in medium with 5% FBS. To
measure spontaneous apoptosis GFP-Jurkat cells were incubated with
medium alone. After incubation for 18±20 h at 37°C the GFP-Jurkat
cells were separated from the skin specimens by resuspending in
medium, washed twice, and subsequently analyzed by a Becton-
Dickinson FACScan using the Cellquest Software. This new method is
based on the observation that living GFP-Jurkat cells can be easily
separated from apoptotic and necrotic cells by their high GFP-associated
¯uorescence activity, which signi®cantly diminishes upon induction of
apoptosis and is almost lost in the case of necrosis (Strebel et al, 2001).
Reagents All reagents that are not further speci®ed were purchased
from Sigma or Fluka chemicals (Fluka Chemie, Buchs, Switzerland).
RESULTS
Expression of death-inducing and death-preventing
molecules in sunlight-protected skin The skin of the
buttock is usually not sunlight exposed and mostly not exposed
to any light at all. In skin biopsy specimens taken from the buttock
CD95L is expressed in the cells of the epidermal basal layer and to
somewhat lower extent also in the upper layers (Fig 2, before UV).
TRAIL is also strongly expressed in the basal layer, but only
marginally in the upper layers (Fig 2, before UV). Whereas CD95
is virtually not expressed or expressed only in low amounts in any
epidermal layer, TRAIL-R1 expression is markedly manifest in the
suprabasal layers and completely absent in the basal layer (Figs 2
and 3). TRAIL-R2 is mainly found in the granular layer (Fig 2).
TRAIL-R3, also called decoy receptor DcR1, and FLIP are
strongly expressed in the basal layer and only weakly in the upper
layers (Fig 2). Bcl-2 expression is restricted to single cells in the
basal layer, whereas p53-expressing keratinocytes are not detected
Figure 1. Detection of FLIP, CD95L, TRAIL, TRAIL-R1,
TRAIL-R2, and TRAIL-R3 (DcR1) by Western blot analysis and
immunostaining. (a) Western blots of split-skin extracts of two
representative individuals stained with antibody to cFLIP, TRAIL-R1,
TRAIL, and CD95L. The speci®city of the antibodies used is shown in
(b) and (c). (b) HL60 extracts stained with immune (i.) or preimmune
(pi.) sera to TRAIL-R2 or R3 (DcR1). (c) HaCaT extracts stained with
immune (i.) or preimmune (pi.) sera to cFLIP, CD95L, TRAIL, and
TRAIL-R1. (d) Skin cryosections were stained with antibody to
TRAIL, TRAIL-R1, TRAIL-R2, and FLIP (open bars) or with antibody
preabsorbed with the corresponding recombinant proteins (TRAIL,
FLIP) (light gray shaded bars) or peptides (TRAIL-R1, TRAIL-R2) or
preadsorbed with the wrong proteins and peptides (dark gray shaded
bars). The staining and reduction of staining were quantitated by
computer-assisted image analysis (see legend to Fig 3).
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in any layer of the epidermis (Fig 2) in accordance with the
literature (Hall et al, 1993). Apoptotic keratinocytes as determined
by the TUNEL technique are very rarely detected (Fig 2, before
UV). On investigating foreskins, which are usually also not sunlight
exposed, a very similar distribution pattern of the various markers
was found (data not shown).
The expression of CD95L, TRAIL, TRAIL-R1, and FLIP in
the epidermis as detected by immunostaining was con®rmed at the
protein level by performing Western blots (Fig 1a). Extracts were
made from normal human split-skin. All extracts expressed CD95L,
TRAIL, TRAIL-R1, and one or two different splice forms of
FLIP. The speci®city of the antibodies used is shown in Fig 1(b±d).
Expression of death-inducing and death-preventing
molecules in UV-light-exposed skin An area of sunlight-
protected skin of the buttock was irradiated with UVB light (0.2 J
per cm2); biopsies were taken before and 14 h, 38 h, 72 h, and
132 h after irradiation; and cryosections and paraf®n sections were
made and stained with the same antibodies as used above. Only the
staining patterns of the time points 38 h and 132 h are shown
(Fig 2). The quantitative assessment by computer-assisted image
analysis of the markers tested in these skin sections is shown in
Fig 4 for all time points. Upon one single UVB light exposure
CD95L expression was slightly increased at 14 h (Fig 4a), but then
decreased in the basal as well as in the upper layers, recovering
somewhat at 132 h (Figs 2, 4a). CD95 expression behaved in the
opposite way, continuously increasing from virtually no or low
expression to marked expression especially in the lower layers of
the epidermis up to 132 h (Figs 2, 4a). This is in line with the
work of other groups who demonstrated UVB-induced CD95
upregulation at the RNA and protein level in keratinocytes
(Leverkus et al, 1997) or at the protein level in mouse skin (Hill et al,
1999; Ouhtit et al, 2000). The expression of TRAIL (Figs 2, 4b)
and FLIP (Fig 4a) only transiently decreased during the 6 d;
however, the expression of the markers tended to expand from the
basal into the upper layers. TRAIL-R1 (Figs 2, 4b) and TRAIL-
R3 (Fig 4b) expression was still strongly manifest 14 h after UV
light exposure, but decreased slightly during the following days.
Apoptotic cells as measured by the TUNEL technique showed up
at 14 h post UV exposure, peaked at 38 h and then decreased again
(Fig 2). At 132 h post UV exposure apoptotic cells were mainly
manifest below the corni®ed layer. P53, not detected before UV
Figure 2. Distribution pattern of apoptosis-
inducing and apoptosis-preventing molecules
in normal skin epidermis and their changes
upon UVB irradiation. A non-sunlight-exposed
skin area was UVB irradiated (0.2 J per cm2),
biopsies were taken before and at several time
intervals after exposure (p.UV), and cryosections
were made and immunostained with antibodies to
CD95L, CD95, TRAIL, TRAIL-R1. For FLIP,
TRAIL-R2 and TRAIL-R3, p53, and Bcl-2 only
immunostainings before UVB irradiation are
shown. Apoptotic cells were determined by the
TUNEL technique. In situ hybridization for
CD95L (CD95L ISH) was done on paraf®n
sections. Scale bar (shown in top left micrograph,
valid for all micrographs): 30 mm.
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irradiation, became strongly expressed at 14 h and then slowly
disappeared (data not shown). Skin biopsies were also taken from
heavily sun-tanned areas of two individuals who had intense sun
exposure over months. The typical pattern of the death-inducing
and death-preventing markers was similar to that in the UVB-
exposed skin with absent expression of CD95L, lower expression of
TRAIL-R1, but marked CD95, TRAIL, and FLIP expression
(Fig 3).
UV-light-mediated downregulation of CD95L is at the
genomic level In order to ®nd out whether the down-
regulation of CD95L upon UV exposure as demonstrated by
immunohistochemistry is at the transcriptional or translational level
ISH experiments were performed. Figures 2 and 4 show that the
ISH signal for CD95L signi®cantly diminished postradiation. Thus,
UV-light-mediated CD95L downregulation is not due to protein
degradation.
Expression of CD95L, TRAIL, TRAIL-R1, and FLIP in AK
and SCC AK are epithelial precancerous lesions and usually a
consequence of long-term solar radiation, which occasionally
progress to invasive SCC. AK and SCC were investigated for the
expression of death-inducing and death-preventing molecules
(Fig 3). Whereas in AK CD95L was virtually not detected in the
basal and suprabasal layers of the lesion similar to long-term sun-
exposed skin, it was again expressed in the dermal nodules of SCC
indicating a transition of CD95L expression during the progression
into invasive SCC. Of interest, in AK intraepidermal zones of
atypical keratinocytes involving the lower portions of the epidermis
showed no expression of TRAIL-R1, whereas TRAIL-R1 and
TRAIL-R2 (data for TRAIL-R2 are not shown) were still
expressed in the suprabasal layers of the intact epidermis but were
absent in the nodules of SCC. CD95, which was expressed in AK,
disappeared in SCC (Fig 3). Both TRAIL and FLIP (Fig 3) tended
to be more strongly expressed in SCC than in AK.
TRAIL and CD95L in healthy human skin are
functional To evaluate whether CD95L and TRAIL in the
epidermis are functional we investigated the lytic capacity of
cutaneous CD95L and TRAIL ex vivo. Small pieces of foreskin
were incubated with GFP-transfected Jurkat cells, which are
sensitive to CD95L- and TRAIL-mediated apoptosis (Strebel et al,
2001) as they express the corresponding receptors. Apoptosis was
measured by ¯ow cytometry after 18±20 h. Figure 5 demonstrates
a marked skin-induced apoptosis of indicator Jurkat cells that was
blocked by the addition of zVAD, a caspase inhibitor, but not by
the control peptide zFA or their solvent dimethylsulfoxide. Soluble
CD95-Fc also signi®cantly blocked apoptosis and a marked but not
signi®cant inhibition was obtained with soluble TRAIL-R-Fc.
The control reagents CD40-Fc or IgG did not block apoptosis.
Split-skin was also used as effectors yielding similar results. For
CD95L-mediated killing similar results were obtained using GFP-
transfected A20 cells as targets. A20 cells, a mouse B lymphoma that
expresses CD95 but neither CD95L, TRAIL, nor TRAIL-R, are
therefore not lyzed by suicide or fratricide by way of upregulation
Figure 3. Distribution of CD95L, CD95,
TRAIL, TRAIL-R1, and FLIP in long-term
sun-exposed skin, AK, and SCC. AK
demonstrates proliferation of atypical keratinocytes
along the basal layer (small arrow) and a negative
staining with CD95L. SCC with aggregates of
invading highly atypical keratinocytes shows a
prominent CD95L expression. CD95 expression is
seen in the lower epidermal layer of AK but is
absent in SCC. There is a strong expression of
TRAIL in the basal and suprabasal layers of AK
and in the lobules of SCC invading the dermis
(large arrow). TRAIL-R1 is expressed in the
suprabasal layers of AK whereas almost all atypical
keratinocytes of the basal layer and the nodules of
SCC in the dermis are negative. FLIP is more
strongly expressed in SCC than AK. The
immunostainings of the cryosection were done as
described in Methods. Scale bar (shown in top left
micrograph, valid for all micrographs): 30 mm.
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of CD95L as recently suggested (Restifo, 2000). In another
approach, cryosections obtained from human skin were overlaid
with GFP-Jurkat cells and apoptosis was subsequently assessed by
¯ow cytometry. Although the apoptosis induced was low (between
5% and 15%) it could also be blocked by zVAD (data not shown).
DISCUSSION
As shown in this report, normal human sunlight-protected
epidermis demonstrates a unique distribution pattern for various
apoptosis-inducing and apoptosis-preventing molecules, but the
expression of some of them signi®cantly changes upon UV light
exposure. The particular expression pattern in the normal epidermis
suggests that these molecules must play an important role for the
maintenance of skin integrity. The basal layer of the epidermis is
central for the renewing skin as it is the primary location of
mitotically active cells maintained by a small population of
epidermal stem cells. Any interference, damage, or transformation
of cells in this layer could therefore lead to the dysregulation of the
balance between cell proliferation, cell differentiation, and cell
death. Therefore, control mechanisms must exist that protect the
normal epidermis from damaging incidents. The marked expression
of the antiapoptotic FLIP and the lack of or low expression of
CD95 and of TRAIL-R1 and TRAIL-R2 in the basal layer of sun-
protected skin prevents uncontrolled apoptosis despite the fact that
CD95L and TRAIL are present. Indeed, in sunlight-protected
epidermis apoptosis is very rarely detected in the basal layer by the
TUNEL technique, in agreement with reports by other groups
(Polakowska et al, 1994; Tamada et al, 1994; Hisa et al, 1995;
Ouhtit et al, 2000). Both CD95L and TRAIL expressed in the
epidermis demonstrate functional activity and kill target cells
expressing the corresponding receptors. Thus, we propose that the
death ligand CD95L and TRAIL function as guardians to maintain
the integrity of the epidermis, especially of the cells of the basal
layer. Both CD95L and TRAIL may prevent the in¯ux of possibly
dangerous cells such as activated lymphocytes or in¯ammatory cells
and avert cell aberration or transformation. Our hypothesis is
supported by the observation that disorders in the epidermis can be
the consequences of changed expression patterns of death ligands.
Indeed, psoriatic plaque lesion development (Gutierrez-Steil et al,
1998) and epidermal necrolysis (Viard et al, 1998) have been clearly
linked to the dysregulation of CD95L expression. We found a
profoundly different expression of some death ligands and death
receptors in AK, a precancerous stage, and in SCC compared to
normal epidermis. Both AK and SCC are direct consequences of
long-term sun exposure. CD95L expression is absent in AK but
present in SCC, whereas the opposite obtains for CD95. TRAIL-
R1 and TRAIL-R2 are only expressed in the zones of normal
epidermis of AK and are absent in the aggregates of atypical
keratinocytes and in SCC. TRAIL and FLIP are strongly expressed
in the tumor nodules and somewhat less in the precancerous area.
Thus, the lack of CD95L, the low expression of TRAIL-R1 and
TRAIL-R2, and the expression of FLIP in AK may prevent the
elimination of these atypical keratinocytes, which then can develop
into invasive tumor cells. Investigations are under way to ®nd out
whether the expression pattern of these molecules can predict the
outcome of AK, i.e., progression to SCC or regression. Moreover,
once a keratinocyte has been transformed and becomes a tumor cell
it upregulates CD95L and downregulates CD95. CD95L and
TRAIL may then prevent the attack of effector cells that express
the corresponding receptors due to their activation, allowing the
growth and expansion of the tumor. A similar mechanism for
CD95L has been shown in immune evasion of BCC (Buechner
et al, 1997). On the other hand, the lack of CD95 and TRAIL-R
may prevent the risk of tumor cell suicide. As both AK and SCC
are the consequence of long-term sun exposure, we investigated
the in¯uence of UVB light on CD95L/CD95 and TRAIL/
TRAIL-R expression in normal human epidermis. We found a
profound change of the pattern of some apoptosis-preventing or
apoptosis-inducing molecules upon one single UVB exposure of
epidermis that was never sunlight-exposed before. CD95L expres-
sion, after a transient increase, decreased whereas CD95 expression
increased over time. A similar UVB-mediated transient increase of
CD95L followed by a decrease has been reported in keratinocytes
(Leverkus et al, 1997) and in mouse skin (Hill et al, 1999).
Moreover, our data in human skin are in close agreement with
those of Ouhtit et al who found an identical situation in acute and
chronic UV-exposed hairless mice (Ouhtit et al, 2000). Upon an
early induction of CD95 and CD95L over 24 h after UV exposure,
CD95 continued to increase whereas CD95L gradually decreased
to background level (Ouhtit et al, 2000). Similar to Ouhtit et al's
results for hairless mice, in human skin the number of apoptotic
cells increased up to 2±3 d post UV exposure and then decreased
again (Ouhtit et al, 2000) and p53 expression paralleled the course
of apoptosis (data not shown). A slight but consistent decrease of
expression was also found for TRAIL and TRAIL-R upon UV
Figure 4. Computer-assisted image analysis to quantify
apoptosis-inducing and apoptosis-preventing molecules in skin
epidermis before and after UVB irradiation. The gray intensity of
arbitrarily chosen epidermal areas was measured and the isotype control
values were subtracted from the antibody values. A gray scale index was
set to 1.0 for the skin sections taken before UVB irradiation with an
exception for CD95, where the index of 1.0 was set to the section taken
at 132 h after UVB exposure. The gray scale intensity of all other
sections was set in relation to the index 1.0. The relative gray scale index
does not take into account that some molecules are differently expressed
in the basal and upper layers. Changes of intensities after UV exposure
were statistically compared to the intensity before UV exposure by
unpaired Student's t test (with the exception of TRAIL and FLIP).
Signi®cant differences (p < 0.05) only are given. (a) Quantitative analysis
of CD95L (closed rectangle), CD95L ISH (open rectangle), CD95 (closed
triangle); (b) quantitative analysis of TRAIL (closed rectangle), TRAIL-R1
(closed circle), TRAIL-R3 (closed triangle), and FLIP (closed inverted triangle).
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exposure. The UV-light-induced downregulation of CD95L was
not due to protein degradation but at the transcriptional level.
Indeed, the DNA-damaging action of UV light is well established.
It has been documented that the enhanced apoptosis early after UV
exposure is due to the elimination of ``sunburn cells'' (DNA-
damaged apoptotic keratinocytes) elicited by the UVB light and
that this keratinocyte death is CD95L and p53 mediated (Hall et al,
1993; Brash, 1996; Henseleit et al, 1997; Hill et al, 1999). Our data
are consistent with this view but in addition postulate that TRAIL-
mediated apoptosis might also be involved. The effect of TRAIL
on transformed cells is well established, whereas the effect on
normal cells is more controversial (Wiley et al, 1995; Walczak et al,
1999). As one single UVB exposure of the human epidermis
already evokes such a marked decrease of CD95L expression within
a few days, it must be postulated that long-term sun and therefore
also UV exposure elicits a persistent downregulation of this death
ligand. Indeed, the epidermis of long-term sun-exposed skin lacks
CD95L and expresses lower levels of TRAIL and TRAIL-R. Thus,
the CD95L/TRAIL-mediated apoptosis to remove ``sunburn cells''
cannot be effective any more in such a skin and the guardian
function of CD95L and TRAIL is lost or heavily impaired. The fact
that in AK TRAIL-R1/R2 and CD95L expression are strongly
diminished supports our hypothesis that loss or downregulation of
TRAIL-R and CD95L increases the risk for tumor formation.
Whether TRAIL- or CD95L-expressing basal keratinocytes also
contribute to the immune privilege of epidermitis by killing
TRAIL-R- or CD95-positive in¯ammatory cells that in®ltrate the
dermo±epidermal junction is currently under investigation.
Taken together, in the normal epidermis CD95L and TRAIL
function as guardian to control possible cell transformations. There
is evidence from experimental and epidemiologic data that long-
term UV exposure is associated with an increased risk for the
development of SCC and BCC. UVB light preferentially down-
regulates CD95L, and somewhat less TRAIL-R1 and TRAIL-R2.
Thus, the surveillance function not only of CD95L but also of
TRAIL is weakened due to missing receptors. Understanding the
molecular mechanisms of the downregulation and upregulation of
these death receptors and death ligands will provide a novel insight
into the pathogenesis of skin diseases and tumors and help the
development of new treatments.
This work was supported by the Swiss National Science Funds grants 31±
51397.97 and 31±64233.0.
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